No Data
Anhui Huaheng Biotechnology Co., Ltd. 2024 annual results forecast
Hua Heng Biology (688639.SH): It is expected that the net income in 2024 will decrease by 51.01% to 59.92% year-on-year.
Gelonghui, January 17 - Huaheng Biological (688639.SH) announced that (1) it is expected to achieve revenue of 2,100 million yuan to 2,300 million yuan for the fiscal year 2024, representing an increase of 161.7319 million yuan to 361.7319 million yuan compared to the same period last year, with a year-on-year growth of 8.34% to 18.66%. (2) It is expected that the net income attributable to the owners of the parent company for fiscal year 2024 will be 180 million yuan to 220 million yuan, a decrease of 229.0615 million yuan to 26,9 compared to the same period last year.
It's Down 28% But Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Could Be Riskier Than It Looks
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) CEO Henghua Guo's Holdings Dropped 6.1% in Value as a Result of the Recent Pullback
Huaheng Biology (688639.SH): Plans to inquire about the transfer of 1.34% of its shares.
On December 20, Gelonghui reported that Huaheng Biological (688639.SH) announced it plans to participate in the pre-IPO share transfer inquiry of Huaheng Biological (hereinafter referred to as "this inquiry transfer") by the shareholder Ningbo Ruiheyuan Venture Capital Partnership (Limited Partnership); the seller intends to transfer a total of 3,357,844 shares, accounting for 1.34% of Huaheng Biological's total share capital.
Anhui Huaheng Biotechnology to Raise Capital of Two Subsidiaries to Boost Production